Nemdx's Mission Is To Inform Patient Diagnosis And Enable Therapeutic Decisions Faster than Ever Before
Nemdx’s proprietary assays are capable of providing a patient’s diagnosis from a sample, in minutes and with high sensitivity and specificity whether identifying cancer genomic mutations, bacteria or proteins.
We assist clinicians to identify the best treatment paths for their patients’ clinical indications, by:
– Detecting cancer mutations in blood samples of cancer patients.
– Gaining rapid insights into tumor heterogeneity by generating histological profile and charactered cancer mutation in the tissue context
In neurodegenerative diseases:
We aim to rapidly identify and, where needed, quantify the presence of disease relevant molecules in blood and/or other relevant body fluids.
the increase in signal over background of a proprietary protein splicing assay
Non Enzymatic Molecular Technologies
Nemdx uses the power of its proprietary non enzymatic molecular technologies to rapidly quantify and characterized specific proteins in patient’s samples:
- Detecting cancer mutations in blood and tumor samples
- Detecting the presence of bacteria in tumors
- Allowing oncologist to rapidly define therapies that will benefit their patients and limit the potential harm associated by long wait times, including patient anxiety.
PROPRIETARY SPLICING DETECTION
PROPRIETARY AMPLIFICATION ASSAY
PROPRIETARY BACTERIA IDENTIFICATION
To enable a first line of early detection of neurodegenerative diseases and cancer, Nemdx is collaborating with leading community, academic, medical and research centres to conduct studies to identify the patterns required to quantify many proteins, detect cancer mutations, and to further explore the interaction between bacteria and cancer.
Powered by a suite of proprietary non-enzymatic molecular technologies, Nemdx is poised to detect RNA, DNA or protein targets rapidly, compared to other tests that may take hours or days.
Cancer Diagnostics And Prognostics
Nemdx offers non-invasive methods to detect mutations, including detecting RNA in exosome derived from blood with high sensitivity and specificity
Nemdx provides rapid detection of cancer mutation in tumor tissues
Nemdx offers rapid quantification of specific proteins in blood or other body fluids
Nemdx’s tests may provide the pharmaceutical industry with easy and cost-efficient assays as companion diagnostics for new drug development by patient stratification through screening and clinical tests.
Nemdx’s tests are not yet commercially available and are currently available only to participants of Nemdx’s research activities. The Nemdx tests are intended to be complementary to, and not a replacement for, U.S. guideline-recommended cancer screening or neurodegenerative testing.